Metformin-dolutegravir interaction leads to metformin-associated lactic acidosis: A case report
Abstract
Metformin, a biguanide, is considered the standard first-line drug for managing type 2 diabetes mellitus (T2DM) patients owing to its safety profile. Despite having a highly safe profile, it is capable of causing serious adverse effects. Biguanides decrease gluconeogenesis from alanine, pyruvate, and lactate, which may result in lactic acidosis. The risk is high in patients with polypharmacy or comorbidities. This is a case of a 48-year-old Indian female with a known case of human immunodeficiency virus (HIV), T2DM, hypothyroidism, and hypertension who presented to the hospital with progressive right-sided weakness for the past 10 days along with transit loss of vision. The patient was diagnosed with multiple central nervous system tuberculomas, for which antitubercular treatment and dexamethasone were started. The patient was on a tenofovir, lamivudine, and dolutegravir regimen for HIV. The patient was started on metformin for sugar control, which led to metformin-associated lactic acidosis. A drug interaction between dolutegravir and metformin was attributed to this. The patient improved after metformin was replaced with glipizide, and lactate levels returned to normal. Lactic acidosis is a rare side effect of metformin. However, the risk of lactic acidosis is high when another drug interferes with metformin pharmacokinetics. Proper assessment and evaluation of potential drug–drug interactions is crucial to assure safe and effective therapy.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.